Since the beginning of 2023, and as of 16 February 2024, six MERS-CoV cases, including two fatalities, have been reported with the date of onset in 2023 by Saudi Arabia (5) and the United Arab Emirates (1).
Since the beginning of 2023, and as of 16 February 2024, six MERS-CoV cases, including two fatalities, have been reported with the date of onset in 2023 by Saudi Arabia (5) and the United Arab Emirates (1).
Since the beginning of 2023, and as of 16 February 2024, six MERS-CoV cases, including two fatalities, have been reported with the date of onset in 2023 by Saudi Arabia (5) and the United Arab Emirates (1).
This protocol presents a common updated methodology to estimate vaccine effectiveness (VE) for COVID-19, using established health data registries in participating European Union and European Economic Area (EU/EEA) countries.
This joint guidance by the ECDC and EMCDDA aims to strengthen the evidence base for developing national strategies for preventing and controlling infections and infectious diseases among people who inject drugs.
Since April 2012, and as of 5 February 2024, a total of 2 617 cases of MERS-CoV, including 947 deaths, have been reported by health authorities worldwide.
Since April 2012, and as of 5 February 2024, a total of 2 617 cases of MERS-CoV, including 947 deaths, have been reported by health authorities worldwide.
This issue of the ECDC Communicable Disease Threats Report (CDTR) the period 4-10 February 2024 and includes updates on avian influenza, measles, MERS-CoV, COVID-19, swine influenza, respiratory virus epidemiology, Western equine encephalitis, Hepatitis E, and the Chinese New Year.
ECDC’s annual surveillance reports provide a wealth of epidemiological data to support decision-making at the national level. They are mainly intended for public health professionals and policymakers involved in disease prevention and control programmes.
This core protocol for ECDC studies of VE against hospitalisation with SARI laboratory-confirmed with SARS-CoV-2 or with influenza, version 3.0, represents an update to the main elements for a multi-country hospital-based study of COVID-19 vaccine effectiveness in patients hospitalised with SARI, initially published as version 1.0 [5], updated to version 2.0 [6].